| Antitumor activity of gefitinib in malignant rhabdoid tumor cells in vitro and in vivo. | |
| | |
MedLine Citation:
|
PMID: 15355927 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: Malignant rhabdoid tumor (MRT) is a rare and highly aggressive neoplasm of young children. Current treatments have had only limited success. Epidermal growth factor receptor (EGFR) was found recently to be expressed on MRT cell lines. Gefitinib (trade name Iressa) is an oral and selective EGFR-tyrosine kinase inhibitor and has been demonstrated to be effective in inhibiting the proliferation of cancer cells in vivo as well as in clinical trials. This encouraged us to examine the antitumor effects of gefitinib on MRT cells in vitro and in vivo. EXPERIMENTAL DESIGN: The expression of EGFR in two MRT tumors and two MRT cell lines (MP-MRT-AN and KP-MRT-NS), established from these two tumor tissues, was examined by immunohistochemistry, immunofluorescence, and immunoblot. The effect of gefitinib on EGFR phosphorylation was examined by immunoblot. The effects of gefitinib on cell growth and apoptosis were examined by cell growth assay and terminal deoxynucleotidyl transferase-mediated nick end labeling assay. The in vivo effect of gefitinib was assessed in athymic mice that had been xenografted with MRT cells. RESULTS: The expression of EGFR was detected in both tumor tissues and cell lines. Gefitinib inhibited EGFR-phosphorylation (IC(50) < 0.1 micromol/L) and in vitro cell growth (IC(50) = approximately 10-12 micromol/L), and a high concentration of gefitinib (20 micromol/L) induced apoptosis in vitro (MP-MRT-AN, 42.9% and KP-MRT-NS, 47.2%). Furthermore, gefitinib at 150 mg/kg had a cytostatic effect on established MRT xenografts (MP-MRT-AN, P = 0.039 and 0.0014; and KP-MRT-NS, P = 0.048 and 0.0086). CONCLUSIONS: Our results demonstrate that gefitinib has antitumor effects in MRT cells in vitro and in vivo and, thus, has promise as a novel and therapeutic strategy for MRT. |
| | |
Authors:
|
Yasumichi Kuwahara; Hajime Hosoi; Shinya Osone; Masakazu Kita; Tomoko Iehara; Hiroshi Kuroda; Tohru Sugimoto |
Related Documents
:
|
10657127 - Rationally designed anti-her2/neu peptide mimetic disables p185her2/neu tyrosine kinase... 1913667 - Epidermal growth factor receptor-reactive monoclonal antibodies: xenograft antitumor ac... 16822827 - Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mu... 1991297 - Receptors for epidermal growth factor and steroid hormones in primary laryngeal tumors. 1317557 - Pleomorphic adenoma of the human female breast. 9591047 - Analysis of the t cell receptor variability of tumor-infiltrating lymphocytes in colore... |
Publication Detail:
|
Type: In Vitro; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Clinical cancer research : an official journal of the American Association for Cancer Research Volume: 10 ISSN: 1078-0432 ISO Abbreviation: Clin. Cancer Res. Publication Date: 2004 Sep |
Date Detail:
|
Created Date: 2004-09-09 Completed Date: 2005-02-15 Revised Date: 2013-06-03 |
Medline Journal Info:
|
Nlm Unique ID: 9502500 Medline TA: Clin Cancer Res Country: United States |
Other Details:
|
Languages: eng Pagination: 5940-8 Citation Subset: IM |
Affiliation:
|
Department of Pediatrics, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kamigyo-ku, Kyoto 602-8566, Japan. kuwahara@koto.kpu-m.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antineoplastic Agents / therapeutic use* Apoptosis / drug effects Cell Division / drug effects Female Fluorescent Antibody Technique Humans Immunoblotting Immunoenzyme Techniques Infant Mice Mice, Inbred BALB C Mice, Nude Phosphorylation / drug effects Quinazolines / therapeutic use* Receptor, Epidermal Growth Factor / antagonists & inhibitors, metabolism* Rhabdoid Tumor / drug therapy*, metabolism, pathology Transplantation, Heterologous Tumor Cells, Cultured |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Quinazolines; EC 2.7.10.1/Receptor, Epidermal Growth Factor; S65743JHBS/gefitinib |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an e...
Next Document: Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patient...